BMS's Opdivo blows Exelixis's Cometriq kidney cancer data out of the water
This article was originally published in Scrip
Executive Summary
Just as Exelixis was finally basking in the glow of positive Phase III progression-free survival data for its anticancer Cometriq in renal cell carcinoma, Bristol-Myers Squibb rained on its parade by stopping the CheckMate-025 study early on positive overall survival data with its immuno-oncology giant Opdivo (nivolumab) in the same setting.